Presidential symposium #ESMO18 - breaking news, STAMPEDE - #radiotherapy to the prostate in hormone naive mPCa; OS benefit in pre-specified subgroup low volume (<4 mets) disease [42% ⬇️ death]. Lancet paper here https://t.co/nM1z7UeghB - is prostate RT new SOC? More data? #pcsm